Is Carl Icahn girding for a renewed war with Biogen Idec's management team? That's the question on Wall Street's mind after hearing the rebellion-prone investor had taken advantage of the recent plunge in the price of Biogen Idec shares to boost his ownership of the company to six percent.
Icahn had backed off of his fight to push the company into a sale after failing to gain enough votes to advance a slate of board members. The Wall Street Journal notes that he has made sounds recently suggesting he may try once again to spur an auction of the company.
- read the story from the Wall Street Journal